Copenhagen, 27 January 2025
Abacus Medicine Pharma Services (AMPS) and Biocodex have agreed a new, exclusive partnership to strengthen the distribution of Diacomit® (stiripentol) in the Nordics. On behalf of Biocodex, AMPS will with immediate effect provide Diacomit for patients in Denmark, Norway and Sweden.
Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome) whose seizures are not adequately controlled with clobazam and valproate.
Mark Ostle, Vice President for Strategic Partnerships at AMPS says: “At Abacus Medicine Pharma Services, we are proud to be the trusted partner of Biocodex to ensure access to this rare disease medicine for patients with Dravet syndrome in the Nordics.”
Hubert Chapellier, Head of International Operations – Rare Diseases at Biocodex continues:
“Abacus Medicine Pharma Services will play a key role to bring sustainable and quality supply of Stiripentol in the Nordics countries. This partnership will enable Biocodex to offer effective and innovative products to patients and families confronted with rare and serious diseases (Dravet syndrome)”.
Dravet syndrome or SMEI is considered a ‘rare disease’, because very few patients suffer from it. In Denmark, for example, it is estimated that fewer than 3 children with the disease are born each year. Dravet syndrome is named after the French paediatrician Charlotte Dravet.
Product information
Strengths and forms:
- Stiripentol (Diacomit) 250 mg powder for oral suspension in sachet,
- Stiripentol (Diacomit) 250mg hard capsules,
- Stiripentol (Diacomit) 500 mg powder for oral suspension in sachet
- Stiripentol (Diacomit) 500mg hard capsules
About Abacus Medicine Pharma Services (AMPS)
AMPS provides end-to-end commercialization solutions for rare disease innovators who want to successfully launch their innovative assets in Europe. Designed for biotech and pharmaceutical firms, we offer solutions that simplify the complex issues involved in multi-market drug launches.
Abacus Medicine Pharma Services (AMPS) is a division of the Abacus Medicine Group. The Group has enjoyed rapid growth over 20 years in operation and today employs more than 1,500 employees across 11 global locations. Total revenue in 2023 was EUR 1,210 million.
About Biocodex
Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Women’s health; Orphan diseases.
The group is present in more than 100 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide.
Contact
Abacus Medicine Pharma Services
Ole Lindhardt, Global Head of Communications and Marketing
Email: oli@abacusmedicine.com
Phone: +45 20 18 39 52
For ordering queries, please contact:
cp-customerservices@abacusmedicine.com
